EPISODE · Oct 15, 2025 · 24 MIN
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
from BiotechTV - News · host BiotechTV
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explain how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function.
Embed this episode
Ready to play
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.